MU-UNMC-1

MU-UNMC-1 blocks the binding of SARS-CoV-2 Spike protein to the ACE2 receptor with an IC₅₀ < 0.25 µM^[1].
MU-UNMC-1 inhibits entry of lentiviral pseudovirus expressing SARS-CoV-2 S protein^[1].
MU-UNMC-1 exhibits antiviral activity against live SARS-CoV-2 with an EC₅₀ of 0.67 µM^[1].
MU-UNMC-1 (0.25-5.00 μM; 1 h) potently blocks the binding of ACE2 and SARS-CoV-2 Spike RBD with an IC₅₀ of < 0.25 μM^[2].
MU-UNMC-1 (0.25-5 μM; 30 min pre-incubation, 48 h post-transduction) shows modest inhibition of SARS-CoV-2 Spike pseudovirus entry in HEK293T-hACE2 cells^[2].
MU-UNMC-1 (0.001-10 μM; 2 h pre-infection, 24 and 48 hpi) exhibits potent antiviral activity against live SARS-CoV-2 in UNCN1T cells with IC₅₀ values of 0.67 μM at 24 hpi and 1.16 μM at 48 hpi^[2].
MU-UNMC-1 (0.001-10 μM; 2 h pre-infection, 24 and 48 hpi) exhibits antiviral activity against live SARS-CoV-2 in Vero-STAT1 knockout cells with IC₅₀ values of 5.35 μM at 24 hpi and 2.94 μM at 48 hpi^[2].
MU-UNMC-1 (0.001-10 μM; 2 h pre-infection, 24 hpi) inhibits SARS-CoV-2 variant B.1.351 and B.1.222 replication in Calu-3 cells with IC₅₀ values of 9.27 μM and 2.64 μM, respectively^[2].
MU-UNMC-1 (Fixed-dose combinations of MU-UNMC-1 and RDV; 2 h pre-infection, 24 hpi) exhibits an antagonistic antiviral effect in SARS-CoV-2 infected UNCN1T cells^[2].
MU-UNMC-1 (0.01-100 μM; 72 h) exhibits cytotoxicity in Vero-STAT1 knockout cells with a CC₅₀ of 6.21 μM^[2].
MU-UNMC-1 (0.01-100 μM; 72 h) exhibits low cytotoxicity in UNCN1T and Calu-3 cells with a CC₅₀ above 100 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.